Exane Derivatives’s Cytokinetics CYTK Stock Holding History

Exane Derivatives’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$2.08K	Hold	53	–	–	﹤0.01%	435
2022 Q1	$1.95K	Hold	53	–	–	﹤0.01%	755
2021 Q4	$2.42K	Hold	53	–	–	﹤0.01%	650
2021 Q3	$1.89K	Sell	53 -1,589	-97%	-$46.8K	﹤0.01%	806
2021 Q2	$30.9K	Hold	1,642	–	–	0.01%	682
2021 Q1	$38.2K	Hold	1,642	–	–	0.01%	536
2020 Q4	$34.1K	Buy	+1,642	New	+$30K	0.01%	486

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Exane Derivatives's CYTK Position: Q2 2022 in Review

Exane Derivatives held its Cytokinetics (CYTK) position steady in Q2 2022 at 53 shares worth $2.08K. The position accounts for ﹤0.01% of the portfolio, ranked #435.

Exane Derivatives first reported a position in CYTK in Q4 2020 and has held it in 7 quarters since. The position peaked at $38.2K in Q1 2021. 262 funds tracked by Wall St. Rank hold CYTK as of Q2 2022.

Exane Derivatives held 53 shares of Cytokinetics worth $2.08K as of Q2 2022.
Exane Derivatives left its Cytokinetics share count unchanged in Q2 2022.
Cytokinetics made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #435 holding.
Exane Derivatives first reported a position in Cytokinetics in Q4 2020 and has held it in 7 quarters since.
Exane Derivatives's Cytokinetics position peaked at $38.2K in Q1 2021.
262 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.